Source:http://linkedlifedata.com/resource/pubmed/id/12553499
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7-8
|
pubmed:dateCreated |
2003-1-29
|
pubmed:abstractText |
Severe sepsis and septic shock are relatively common problems in intensive care. The mortality in septic shock is still high, and the main causes of death are multiple organ failure and refractory hypotension. Impaired tissue perfusion due to hypovolemia, disturbed vasoregulation and myocardial dysfunction contribute to the multiple organ dysfunction. Treatment of hemodynamics in septic shock consists of appropriate fluid therapy guided by invasive monitoring combined with vasoactive drugs aiming to correct hypotension and inappropriately low cardiac output. The drug of choice for low vascular resistance is norepinephrine, while insufficient myocardial contractility is commonly treated with dobutamine. The use of norepinephrine seems to be associated with better prognosis as compared to results from the use of dopamine or epinephrine. In septic shock, vasopressin levels are low, and therefore, vasopressin has been advocated as a vasopressor. Its effectiveness and safety have not yet been documented, and so far it is regarded as an experimental treatment Recent data support the use of corticosteroid, at least in some of the patients with septic shock. Also, activated protein C, a drug with anti-inflammatory and antithrombotic properties, decreases mortality in patients with septic shock.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Dobutamine,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Vasopressins
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0785-3890
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
590-7
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:12553499-Adrenal Cortex Hormones,
pubmed-meshheading:12553499-Dobutamine,
pubmed-meshheading:12553499-Fibrinolytic Agents,
pubmed-meshheading:12553499-Fluid Therapy,
pubmed-meshheading:12553499-Humans,
pubmed-meshheading:12553499-Myocardial Contraction,
pubmed-meshheading:12553499-Myocardium,
pubmed-meshheading:12553499-Norepinephrine,
pubmed-meshheading:12553499-Perfusion,
pubmed-meshheading:12553499-Resuscitation,
pubmed-meshheading:12553499-Shock, Septic,
pubmed-meshheading:12553499-Vasopressins
|
pubmed:year |
2002
|
pubmed:articleTitle |
Treatment of impaired perfusion in septic shock.
|
pubmed:affiliation |
Department of Intensive Care, Kuopio University Hospital, PO Box 1777, FI-70210 Kuopio, Finland. esko.ruokonen@kuh.fi
|
pubmed:publicationType |
Journal Article,
Review
|